Evaluation of the Pharmacokinetics, Safety, Tolerability and Efficacy of Entecavir (ETV) in Pediatric Subjects With Chronic Hepatitis B Virus (HBV) Infection Who Are HBeAg-Positive

Trial Profile

Evaluation of the Pharmacokinetics, Safety, Tolerability and Efficacy of Entecavir (ETV) in Pediatric Subjects With Chronic Hepatitis B Virus (HBV) Infection Who Are HBeAg-Positive

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Entecavir (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 18 Jun 2016 Results assessing population pharmacokinetic from five trials published in the Clinical Pharmacokinetics
    • 01 Oct 2013 Results will be presented at the 64th Annual Meeting of The American Association for the Study of Liver Diseases (AASLD) according to a Bristol-Myers Squibb media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top